

# Michael J Roy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7275800/publications.pdf>

Version: 2024-02-01

10  
papers

737  
citations

1163117

8  
h-index

1281871

11  
g-index

14  
all docs

14  
docs citations

14  
times ranked

903  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct PEAK3 interactors and outputs expand the signaling potential of the PEAK pseudokinase family. <i>Science Signaling</i> , 2022, 15, eabj3554.	3.6	8
2	Production and purification of the PEAK pseudokinases for structural and functional studies. <i>Methods in Enzymology</i> , 2022, 667, 1-35.	1.0	4
3	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X <sub>L</sub> and BCL-2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5447-5469.	6.4	5
4	Synthesis of C-Mannosylated Glycopeptides Enabled by Ni-Catalyzed Photoreductive Cross-Coupling Reactions. <i>Journal of the American Chemical Society</i> , 2021, 143, 12699-12707.	13.7	39
5	Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1. <i>Communications Biology</i> , 2021, 4, 1105.	4.4	17
6	The PEAK family of pseudokinases, their role in cell signalling and cancer. <i>FEBS Journal</i> , 2020, 287, 4183-4197.	4.7	20
7	BAK core dimers bind lipids and can be bridged by them. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 1024-1031.	8.2	49
8	SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. <i>ACS Chemical Biology</i> , 2019, 14, 361-368.	3.4	212
9	BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. <i>Nature Chemical Biology</i> , 2019, 15, 672-680.	8.0	335
10	De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-X <sub>L</sub> : Synthesis, Structural and Biochemical Characterization. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1323-1343.	6.4	33